Reliq Health Technologies Inc (RQHTF) Fair Value & Analysis
Healthcare · US · Market cap $2.0M
Reliq Health Technologies Inc
RQHTF · US
Fair value as of: Jun 26, 2026
From 1 valuation models · updated 21 days ago
Fair value updated Jun 26, 2026, revised from $0.1000 to $0.0110 (−89.0%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range $0.0001 – $0.2857 · fair‑value band $0.0100 – $0.0120 · the $0.0100 price screens below the $0.0110 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Reliq Health Technologies Inc (RQHTF) currently trades at $0.0100, while our model-based Fair Value estimate is $0.0110, implying the stock looks roughly 10.0% undervalued today. We read business quality at 36/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, Reliq Health Technologies Inc generated revenue of $14.6M at a net margin of -3.1%. Revenue grew 88.5% year over year. It earns a return on equity of -4.5%. Fundamentals as of Jun 26, 2026
Our scenario range runs from $0.0100 (bear case) to $0.0120 (bull case); at $0.0100, the current price sits within that range. The share trades about 33% below its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -37% fair-value upside, at 10%, RQHTF screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Reliq Health Technologies Inc., a healthcare technology company, develops secure telemedicine and virtual care solutions for the healthcare market. It provides iUGO Care platform, a software as a solution that allows complex patients to receive care in the home. The company was formerly known as Moseda Technologies Inc. and changed its name to Reliq Health Technologies Inc. in May 2016. Reliq Health Technologies Inc. was incorporated in 2005 is headquartered in Hamilton, Canada.
Revenue & earnings trend
FY2018 – FY2022 · reported fiscal years
Reliq Health Technologies Inc reported revenue of $8.6M in FY2022 versus $2.3M in FY2018, a compound +39.3%/yr. Reported net income was −$8.2M in FY2022.
Is RQHTF fairly valued? → Check now
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $153.16 | $183.66 | +20% |
| Pro Medicus Limited PME | A$161.58 | A$33.82 | -79% |
| BrightSpring Health Services, Inc BTSG | $60.59 | $23.87 | -61% |
| Tempus AI, Inc TEM | $48.61 | $12.67 | -74% |
| HealthEquity, Inc HQY | $86.03 | $54.47 | -37% |
| Hinge Health, Inc HNGE | $68.85 | $78.43 | +14% |
| M3, Inc MTHRY | $5.03 | $7.44 | +48% |
| 10x Genomics, Inc TXG | $29.11 | $17.86 | -39% |
| Waystar Holding WAY | $20.00 | $14.86 | -26% |
| Ping An Healthcare and Technology Company PANHF | $0.9000 | $0.5700 | -37% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Reliq Health Technologies Inc (RQHTF) undervalued?
What is the fair value of RQHTF?
What is the quality score of RQHTF?
What is the revenue of Reliq Health Technologies Inc (RQHTF)?
What is the net profit margin of RQHTF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Reliq Health Technologies Inc analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.